

Financial Tear Sheet


Corporate Profile

Amgen, the world's largest biotechnology company, uses science and innovation in an effort to dramatically improve people's lives. Amgen aspires to be the world's best human therapeutics company.

Our researchers harness the powerful tools of cellular and molecular biology and medicinal chemistry to discover, develop and commercialize naturally occurring proteins, antibodies and small molecules, with the goal of extending the reach of science to unleash the body's own powerful therapeutic responses. Amgen's research and product development programs aim to help patients in four critical areas: nephrology, hematology and oncology, bone and inflammation, neurology and endocrinology.

Stock Performance

AMGN (COMMON STOCK)	
Exchange	NASDAQ (US Dollar)
Price	\$167.29
Change (%)	▼ 0.52 (0.31%)
Volume	1,741,936
52 Week Low	\$133.64
Market Cap	\$122,067,292,775
Rolling EPS	10.98
PE Ratio	15.2359
Shares Outstanding	729,674,773



Data as of 08/18/17 4:00 p.m. ET

Recent Headlines

08/17/17

Amgen And Humana Partner For Improved Health Outcomes And Efficiency

08/16/17

Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine

07/31/17


Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis

Upcoming Events

There are currently no events scheduled.

Analyst Estimates / Ratings

Mean Recommendation: **2.4**



EPS TREND

		Current	30 Days Ago	90 Days Ago
QTR	Sep 17	3.11	3.12	3.13
QTR	Dec 17	3.09	3.10	3.10
QTR	Mar 18	3.13	3.10	3.08
QTR	Jun 18	3.16	3.13	3.10
FY	Dec 17	12.57	12.45	12.46
FY	Dec 18	12.81	12.76	12.69

SEC Filings

FILING DATE	FORM
08/15/17	CT ORDER
08/04/17	4
08/02/17	4
08/02/17	SC 13G/A

Financial Reports

Q2 2017 Financial Results

Presentations

08/07/17 Investor Insights Newsletter - Q2 2017

Data provided by Nasdaq. Minimum 15 minutes delayed.